Copyright
©The Author(s) 2024.
World J Virol. Jun 25, 2024; 13(2): 90668
Published online Jun 25, 2024. doi: 10.5501/wjv.v13.i2.90668
Published online Jun 25, 2024. doi: 10.5501/wjv.v13.i2.90668
Table 4 Proportion of patients who experienced prolongation of QTc after treatment
| Treatment | QTc, ≥ 500 ms | QTc, < 500 ms | P value | QTc increase, 80 ms | No QTc irncrease | P value | ||||
| n | % | n | % | n | % | n | % | |||
| HCQ-AZI | 4 | 3.3 | 117 | 96.7 | 0.047 | 5 | 4.1 | 116 | 95.9 | 0.021 |
| Doubase C | 0 | 0 | 137 | 100 | 0 | 0 | 137 | 100 | ||
- Citation: Madioko Makanzu B, Makulo JR, Ndona Mandina M, Wumba DR, Mashi Longokolo M, Situakibanza H, Odio O, Sonzi Mangala D, Mihigo Bashengezi C, Kabwe Mwilambwe B, Kabanda Kurhenga G, Longo-Mbenza B, Mwimba Mbungu R. Hydroxychloroquine-azithromycin, doubase C, and QTc prolongation in congolese patients with COVID-19: Myth or reality? World J Virol 2024; 13(2): 90668
- URL: https://www.wjgnet.com/2220-3249/full/v13/i2/90668.htm
- DOI: https://dx.doi.org/10.5501/wjv.v13.i2.90668